Pharmacokinetic, pharmacodynamic, and tolerability profiles of the. Pharmacokinetic and pharmacodynamic evaluation of linagliptin for. Population pharmacokinetics and pharmacodynamics of linagliptin in patients with type 2 diabetes mellitus article pdf available in clinical pharmacokinetics 547 january 2015 with 1 reads. Clinical pharmacokinetics is the application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Peak plasma concentrations usually attained within 1. Pharmacokinetics, pharmacodynamics and tolerability of. Population pharmacokinetics and pharmacodynamics of.
Silke retlich, vincent duval, ulrike graefemody, christian friedrich, sanjay patel, ulrich jaehde and alexander staab, population pharmacokinetics and pharmacodynamics of linagliptin in patients with type 2 diabetes mellitus, clinical pharmacokinetics, 54, 7, 737, 2015. This was an open label, multicentre phase i trial to study the pharmacokinetics and pharmacodynamics of the dipeptidyl peptidase. Introduction to pharmacokinetics and pharmacodynamics. The pk and metabolism of linagliptin were investigated further in healthy. Use the link below to share a fulltext version of this article with your friends and colleagues. The features of linagliptin will be compared with other drugs in its class.
The pharmacokinetics and pharmacodynamics of linagliptin have been evaluated in healthy subjects 57 and in patients with t2dm 3. Request pdf clinical pharmacokinetics and pharmacodynamics of linagliptin linagliptin is an orally active smallmolecule inhibitor of. Fixedcombination tablets of linagliptin and empagliflozin or linagliptin and immediaterelease metformin hydrochloride are bioequivalent to singleentity tablets of linagliptin given. Population pharmacokinetics and pharmacodynamics of linagliptin in patients with type 2 diabetes mellitus article pdf available in clinical pharmacokinetics 547. Development of linagliptin included a clinical pharmacology. The pharmacokinetics and pharmacodynamics of linagliptin have been evaluated in healthy subjects 57 and in patients with t2dm. Abstract our aims were to summarize the clinical pharmacokinetics and pharmacodynamics of the dipeptidyl. Linagliptin has a unique pharmacokinetic and pharmacodynamic profile within the dpp4 inhibitor class 14.
Pdf population pharmacokinetics and pharmacodynamics of. Although most clinical trials of linagliptin have involved largely caucasian. Trajenta, innlinagliptin european medicines agency europa eu. Linagliptin is the first and thus far the only dpp4 inhibitor, and oral antihyperglycaemic drug in general, to be approved as a singlestrength oncedaily. Similarly, linagliptin does not determine any relevant and clinical meaningful change in the pharmacokinetics of metformin, sulfunylureas, digoxin, warfarin, simvastatin and oral contraceptive. Pharmacology, efficacy, and safety of linagliptin for the. Linagliptin is an orally active smallmolecule inhibitor of dipeptidyl peptidase dpp4, which was first licensed in the us, europe, japan and other territories in 2011 to improve glycaemic control in adults with type 2 diabetes mellitus. Linagliptin pharmacokinetics absorption bioavailability.
1087 1320 489 876 13 832 661 1436 394 1146 1044 1110 817 1151 890 256 704 921 1267 1118 1388 1421 1301 570 256 753 333 489 1268 1482 1426 1523 1328 1072 721 1130 1036 587 679 305 1317 606 798 581 2 318 960